At a glance
ClinicalIndex Comparison RecordN/ACompleted· 132 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
In Brief
An observational study for Survival Outcomes of Patients With Pulmonary LCNEC. Completed, enrolled 132 participants.
Detailed Summary
This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern centres in Poland. The group of patients consists of 47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period ranged from 0 to 192 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2002
Primary CompletionDec 2018
First PostedJun 2019
TodayJul 2026
First PostedJun 26, 2019
Enrollment StartJan 1, 2002
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 17 yearsPosted 7.0 years ago